Daewoong to enter the major psychotic markets

Published: 2005-08-29 06:56:00

Updated: 2005-08-29 06:56:00

Daewoong (CEO: Yoon Jae-seung) announced to launch Spendalin (Risperidone) 2mg tablet, a drug for schizophrenia in the middle of Aug. aiming at an active entry of major psychotic drug markets.

Spendalin (Risperidone) improves a positive and negative symptom of mental disorders by blocking both...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK